The estimated Net Worth of Vicki Kelemen is at least $14 Tisíc dollars as of 23 March 2021. Ms Kelemen owns over 960 units of Cardiff Oncology stock worth over $13,982 and over the last 4 years she sold CRDF stock worth over $0.
Sign up
Ms Kelemen CRDF stock SEC Form 4 insiders trading
Ms has made over 3 trades of the Cardiff Oncology stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 960 units of CRDF stock worth $9,898 on 23 March 2021.
The largest trade she's ever made was exercising 35,321 units of Cardiff Oncology stock on 23 November 2020 worth over $87,596. On average, Ms trades about 6,059 units every 20 days since 2020. As of 23 March 2021 she still owns at least 6,053 units of Cardiff Oncology stock.
You can see the complete history of Ms Kelemen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Vicki Kelemen biography
Vicki Kelemen is the Exec. VP & COO at Cardiff Oncology.
What's Ms Kelemen's mailing address?
Vicki's mailing address filed with the SEC is C/O CARDIFF ONCOLOGY, INC., 11055 FLINTKOTE AVE, SAN DIEGO, CA, 92121.
Insiders trading at Cardiff Oncology
Over the last 5 years, insiders at Cardiff Oncology have traded over $0 worth of Cardiff Oncology stock and bought 966,810 units worth $1,962,891 . The most active insiders traders include Gary W Pace, Gary S Jacob a Mark Erlander. On average, Cardiff Oncology executives and independent directors trade stock every 41 days with the average trade being worth of $74,449. The most recent stock trade was executed by Gary W Pace on 19 December 2023, trading 30,000 units of CRDF stock currently worth $41,100.
What does Cardiff Oncology do?
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics;CY140, an inhibitor of PLK1, PLK2 and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials;TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
What does Cardiff Oncology's logo look like?
Complete history of Ms Kelemen stock trades at Cardiff Oncology
Cardiff Oncology executives and stock owners
Cardiff Oncology executives and other stock owners filed with the SEC include:
-
Dr. Mark Erlander,
CEO & Director -
Charles Monahan R.Ph.,
Sr. VP of Regulatory Affairs -
Dr. Tod Smeal Ph.D.,
Chief Scientific Officer? -
Dr. Katherine L. Ruffner M.D.,
Chief Medical Officer -
James E. Levine,
Chief Financial Officer -
Elizabeth Anderson,
VP of Fin. & Admin. -
Vicki Kelemen,
Exec. VP & COO -
Brigitte Lindsay,
VP of Fin. -
Lale White,
Director -
James O Armitage,
Director -
Gary W Pace,
Director -
Thomas Phd Adams,
-
Rodney S Markin,
Director -
Vicki Kelemen,
Exec. VP and COO -
Mark Erlander,
Chief Executive Officer -
Renee P Tannenbaum,
Director -
Gary S Jacob,
-
James E. Levine,
Chief Financial Officer -
Katherine L Ruffner,
Chief Medical Officer -
John P Brancaccio,
-
Tod Smeal,
Chief Scientific Officer -
Fairooz Kabbinavar,
Chief Medical Officer